Risvutatug Rezetecan not checked

GSK

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
4 active
4 in total · 3 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
Tested for
Neoplasms, Lung (2 trials), Neoplasms, Prostate, Gastrointestinal Neoplasms
Main trialPhase 3
“In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether Ris-Rez is safe and tolerated well by participants compared to topotecan and provide a better…”In the company’s words, NCT07099898 on ClinicalTrials.gov

Other drugs for Neoplasms, Lung

All 676 drugs for Neoplasms, Lung

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 5 Nov 2027 A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
Phase 3Recruiting 5 Dec 2029 A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
Phase 1/2Recruiting 9 Jan 2029 A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Phase 1/2Recruiting 22 Jun 2029 A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Risvutatug Rezetecan

Following is part of Solo: you see every change to Risvutatug Rezetecan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in